舒利迭治疗支气管哮喘合并肺结核患者的疗效观察

The clinical observation on Seretide for bronchial asthma patients of pulmonary tuberculosis patients

目的:探讨舒利迭治疗支气管哮喘合并肺结核患者的临床疗效。方法:选取100例支气管哮喘合并肺结核患者,按照入院顺序,将其分为两组,对照组(n=50)给予布地奈德吸入治疗,治疗组(n=50)给予舒利迭吸入治疗;12周的疗程结束后,评价两组患者的疗效差异。结果:治疗组患者的咳嗽、呼吸困难、肺部哮鸣音等症状的消失时间均明显小于对照组,经比较,差异具有统计学意义(P<0.05)。两组患者治疗前的FEV1占预计值百分比,PEF占预计值百分比比较,差异无统计学意义(P>0.05)。治疗组患者,经舒利迭治疗,治疗4周、8周及12周的FEV1占预计值百分比,PEF占预计值百分比与对照组比较,差异具有统计学意义(P<0.05)。结论:采用舒利迭治疗支气管哮喘合并肺结核,可迅速控制咳嗽、呼吸困难、肺部哮鸣音等症状,改善肺功能,且未见肺结核复发,值得临床推广应用。

Objective To investigate the nimesulide overlapping clinical curative effect for the treatment of bronchial asthma combined tuberculosis patient. Method 100 cases of bronchial asthma with tuberculosis patients were selected, according to ad-mission order,they were divided into two groups, control group （n =50） were given budesonide inhalation therapy,the treatment group （n =50） wer given Seretide overlapping inhalation therapy; After 12 weeks of treatment,to evaluate the effect of two groups of patients. Results The treatment group patients with symptoms such as cough, shortness of breath, wheezing sound the lungs of the disappearance of the time were significantly less than the control group,by comparison, the difference was statistically signifi-cant （P 〈0. 05）. Two groups of patients before treatment of FEV1 percentage of expected value,PEF take up of the expected val-ue comparison,there was no statistically significant difference （P 〉0. 05）. Treatment group patients by Seretide overlapping treat-ment,4 weeks,8 weeks and 12 weeks of FEVI percentage of expected value,PEF take up of the expected value compared with control group, the difference was statistically significant （ P 〈 0. 05 ）. Conclusion Seretide overlapping treating bronchial asthma with tuberculosis, can rapidly control symptoms such as cough, difficulty breathing, lung wheezing sound, improve lung function, and no recurrence of tuberculosis, worthy of clinical popularization and application.